NXL Stock Summary and Trading Ideas (Nexalin Technology | NASDAQ:NXL)

Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.

Nexalin Technology trades on the NASDAQ stock market under the symbol NXL.

As of April 29, 2026, NXL stock price declined to $0.35 with 98,911 million shares trading.

NXL has a beta of 1.74, meaning it tends to be more sensitive to market movements. NXL has a correlation of 0.07 to the broad based SPY ETF.

NXL has a market cap of $7.14 million. This is considered a Sub-Micro Cap stock.

Last quarter Nexalin Technology reported $171,895 in Revenue and -$.13 earnings per share. This beat revenue expectation by $91,895 and missed earnings estimates by -$.01.

In the last 3 years, NXL traded as high as $4.49 and as low as $.25.

The top ETF exchange traded funds that NXL belongs to (by Net Assets): VXF.

NXL has underperformed the market in the last year with a price return of -80.9% while the SPY ETF gained +30.5%. NXL has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -42.2% and -19.3%, respectively, while the SPY returned +2.6% and +2.5%, respectively.

NXL support price is $.34 and resistance is $.40 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NXL shares will trade within this expected range on the day.